Gemmer Asset Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Gemmer Asset Management’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-3	Closed	–	–	1302
2016 Q1	$0	Hold	3	–	–	﹤0.01%	1340
2015 Q4	$0	Hold	3	–	–	﹤0.01%	1324
2015 Q3	$0	Hold	3	–	–	﹤0.01%	1352
2015 Q2	$0	Hold	3	–	–	﹤0.01%	1388
2015 Q1	$0	Hold	3	–	–	﹤0.01%	1450
2014 Q4	$0	Hold	3	–	–	﹤0.01%	1482
2014 Q3	$0	Hold	3	–	–	﹤0.01%	1506
2014 Q2	$0	Hold	3	–	–	﹤0.01%	1501
2014 Q1	$0	Buy	+3	New	+$49	﹤0.01%	1433

Other funds holding CASC

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

EAM

EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Gemmer Asset Management's CASC Position: Q2 2016 in Review

Gemmer Asset Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q2 2016, closing a stake of 3 shares.

Gemmer Asset Management first reported a position in CASC in Q1 2014 and held it in 9 quarters. The position peaked at $0 in Q1 2016. 75 funds tracked by Wall St. Rank hold CASC as of Q2 2016.

Gemmer Asset Management reported no remaining Cascadian Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
Gemmer Asset Management sold 3 Cascadian Therapeutics, Inc. shares in Q2 2016.
Gemmer Asset Management first reported a position in Cascadian Therapeutics, Inc. in Q1 2014 and held it in 9 quarters.
Gemmer Asset Management's Cascadian Therapeutics, Inc. position peaked at $0 in Q1 2016.
75 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q2 2016.

Based on Gemmer Asset Management's 13F filing for Q2 2016, filed 22 Jul 2016.